Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial
Authors:
Open Access
- 4 October 2024
- journal article
- research article
- Published by Elsevier in The Lancet Microbe
- Vol. 5 (11) , 100923-10
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Urgent considerations for booster vaccination strategies against Ebola virus diseaseThe Lancet Infectious Diseases, 2024
- Randomized Trial of Vaccines for Zaire Ebola Virus DiseaseNew England Journal of Medicine, 2022
- A Longitudinal Study of Ebola Sequelae in LiberiaNew England Journal of Medicine, 2019
- Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assayJournal of Virological Methods, 2018
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)The Lancet, 2017
- A Recombinant Vesicular Stomatitis Virus Ebola VaccineNew England Journal of Medicine, 2017
- Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodiesNature Medicine, 2016
- Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming EffectThe Journal of Infectious Diseases, 2013
- DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval–Dependent Manner in AdultsThe Journal of Infectious Diseases, 2013
- Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and ArenavirusesJournal of Virology, 2004